证券代码：600713 证券简称：南京医药 编号：ls2025-109 2025 年 6 月 23-25 日，公司第十届董事会临时会议审议通过《关于公司公开 挂牌出租南京市秦淮区延龄巷 27 号房地产的议案》。董事会同意公司公开挂牌 出租标的资产，挂牌出租起始年租金租赁价格为 711.55 万元/年（人民币，下同）。 出租总面积 13,325.11 平方米（以实际可租赁面积为准），租赁期限为 13 年（156 个月，免租期为 6 个月，租赁期前三年均摊）。租金按季支付，租金单价前三年 不变，第四年起开始递增，每三年在上一年租金的基础上递增 5%，租赁期的租 金总收入预计为 9,709.73 万元。最终成交价格及承租人根据公开挂牌结果予以确 定。董事会同时授权公司经营层具体办理上述资产挂牌出租相关事宜。详情请见 公司于 2025 年 6 月 26 日对外披露的编号为 ls2025-093 之《南京医药股份有限公 司关于公开挂牌出租南京市秦淮区延龄巷 27 号房地产的公告》。 二、挂牌进展情况 2025 年 7 月 16 日至 2025 年 7 月 29 日，标的资产在南京市公共资源交易中 心挂牌，公开征集承租人 ...

Core Points - Nanjing Pharmaceutical Co., Ltd. announced the progress of leasing a property located at 27 Yanling Lane, Qinhuai District, Nanjing [1] - The board of directors approved the public listing for lease from June 23 to June 25, 2025, with an initial annual rent of 7.1155 million yuan and a lease term of 13 years, expecting total rental income of 97.0973 million yuan [1] - The solicitation for tenants took place from July 16 to July 29, with only Wangu Enterprise Management Group Co., Ltd. meeting the qualification criteria [1] - On August 20, the company received a confirmation of transaction, with Wangu Company as the lessee at the agreed price of 7.1155 million yuan per year, totaling 97.0973 million yuan [1] - Wangu Company has a registered capital of 66.6667 million yuan and is not related to Nanjing Pharmaceutical [1]

Core Points - Nanjing Pharmaceutical announced the use of 170 million yuan of temporarily idle raised funds to purchase a large corporate time deposit from Minsheng Bank, which matured on August 19, 2025 [2] - The company redeemed the principal of 170 million yuan and earned investment income of 573,800 yuan, which met expectations [2] - The company plans to continue using the same amount of 170 million yuan to purchase another large time deposit from Minsheng Bank with a term of 3 months and an annualized yield of 1.10% [2]

Core Viewpoint - The pharmaceutical distribution industry is characterized by three main business models: wholesale, retail, and various new distribution models, each with distinct operational dynamics and market implications [1]. Group 1: Wholesale Model - The wholesale model, also known as the distribution model, involves selling pharmaceuticals and medical devices in bulk to entities that directly interact with consumers, such as medical institutions and retail pharmacies [4]. - The third terminal in the wholesale model is increasingly favored by internet hospitals, indicating a shift towards digital integration in pharmaceutical distribution [4]. Group 2: Retail Model - The retail model involves retail pharmacies purchasing pharmaceutical products from manufacturers or other distributors and selling them to individual consumers, generating profit from the price difference [7]. - Although the retail model operates on a smaller scale compared to wholesale, it boasts higher profit margins, making it an attractive segment within the pharmaceutical distribution landscape [7]. Group 3: Internet Retail Model - The internet retail model encompasses various online platforms, including internet hospitals and pharmaceutical e-commerce, facilitating diagnosis and drug sales through digital channels [9]. - This model includes B2B, B2C, and O2O formats, reflecting the growing trend of digital transformation in the pharmaceutical sector [9]. Group 4: Third-Party Cold Chain Logistics - The "14th Five-Year Plan" emphasizes the need for a modern, intelligent pharmaceutical supply chain, focusing on enhancing networked, scaled, and specialized logistics services [12]. - Third-party cold chain logistics offer significant advantages, such as reducing initial investment costs for pharmaceutical companies and ensuring temperature-controlled transport, which is crucial for maintaining drug quality [12]. - These logistics providers can effectively manage reverse logistics and product recalls through advanced tracking and data exchange systems, thereby minimizing losses and ensuring compliance with quality standards [12].

批发模式中第三终端受互联网医院青睐 转自：前瞻产业研究院 行业主要上市公司：国药控股(01099.HK);上海医药(601607.SH);华润医药(03320.HK);九州通 (600998.SH);南京医药(600713.SH);华东医药(000963.SZ);英特集团（维权）(000411.SZ)等 医药流通行业主要商业模式可分为三类 医药商业是医药行业的子行业之一，是专门从事医药商品经营活动的独立经济分支，主要负责药品在市 场上的流通。医药流通行业主要商业模式可分为批发模式、零售模式和各类新型流通模式三类。批发毛 利率较低其中又分为纯销、快批和调拨等;零售毛利率较高药品零售企业一般就是所谓的零售药店是直 接面对最终消费者患者的商品流通环节也是药品流通的最终环节。 批发模式即分销模式，是指批量将药品和医疗器械销售给直接接触消费者的最后环节，包括医疗机构、 零售药店、基层医疗机构等或下游分销商。根据销售对象的不同批发模式可进一步区分为以下几类：医 院直销：商业调拨、第三终端。此外由于渠道下沉、分散等特点，第三终端目前也是各互联网医药企业 积极布局的市场。 零售模式规模小但毛利率高 零售模式是指零售药店从医药 ...

Market Overview - The pharmaceutical commercial sector increased by 0.05% on August 20, with Yifeng Pharmacy leading the gains [1] - The Shanghai Composite Index closed at 3766.21, up 1.04%, while the Shenzhen Component Index closed at 11926.74, up 0.89% [1] Stock Performance - Yifeng Pharmacy (603939) closed at 24.27, up 0.87% with a trading volume of 58,700 shares and a turnover of 141 million yuan [1] - Other notable performers include: - Liuyuan Group (603368) at 18.64, up 0.76% [1] - China National Pharmaceutical Group (600511) at 30.01, up 0.60% [1] - Shanghai Pharmaceuticals (601607) at 19.02, up 0.58% [1] - Nanjing Pharmaceutical (600713) at 5.30, up 0.57% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 377 million yuan from institutional investors, while retail investors saw a net inflow of 367 million yuan [2] - Notable capital flows include: - Yifeng Pharmacy had a net outflow of 9.79 million yuan from institutional investors [3] - Heavy Drug Holdings (000950) saw a net inflow of 7.45 million yuan from institutional investors [3] - Drug Easy Purchase (300937) had a net inflow of 3.82 million yuan from institutional investors [3]

证券代码：600713 证券简称：南京医药 编号：ls2025-108 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 2025 年度第二期超短期融资券兑付公告 为保证南京医药股份有限公司 2025 年度第二期超短期融资券（债券简称：25 南京医药 SCP002，债券代码：012580666）兑付工作的顺利进行，现将有关事宜 公告如下： （一）发行人：南京医药股份有限公司 联系人：周昊鹏 联系方式：025-84552638 （二）存续期管理机构：杭州银行股份有限公司 联系人：王心悦 联系方式：0571-86475508 （三）登记托管机构：银行间市场清算所股份有限公司 联系部门：运营部 联系人：谢晨燕、陈龚荣 联系方式：021-23198708、021-23198682 | 发行人名称 | 南京医药股份有限公司 | | | --- | --- | --- | | 债项名称 | 南京医药股份有限公司 2025 | 年度第二期 | | | 超短期融资券 | | | 债项简称 | 南京医药 25 | SCP002 | | 债项代码 | 012580666 | | | 发行金额（万元） | 50,0 ...

证券代码：600713 证券简称：南京医药 编号：ls2025-107 债券代码：110098 债券简称：南药转债 2024 年度第三期超短期融资券兑付公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为保证南京医药股份有限公司 2024 年度第三期超短期融资券（债券简称：24 南京医药 SCP003，债券代码：012483960）兑付工作的顺利进行，现将有关事宜 公告如下： | 发行人名称 | 南京医药股份有限公司 | | --- | --- | | 债项名称 | 南京医药股份有限公司 2024 年度第三期超 | | | 短期融资券 | | 债项简称 | 24 南京医药 SCP003 | | 债项代码 | 012483960 | | 发行金额（万元） | 50,000 | | 起息日 | 2024-12-17 | | 发行期限 | 269 天 | | 债项余额（万元） | 50,000 | | 最新评级情况 | / | | 偿还类别 | 本息兑付 | | 本计息期债项利率 | 1.8% | | 本息兑付日 | 2025- ...

| | | 债券代码：110098 债券简称：南药转债 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 现金管理产品名称：南京医药股份有限公司（以下简称"公司"）本次 使用部分暂时闲置募集资金 1.7 亿元购买民生银行单位大额存单。 南京医药股份有限公司关于公司及子公司 使用部分暂时闲置募集资金进行现金管理到期赎回并继续 进行现金管理的公告 履行的审议程序：公司于2025年1月20-22日召开了第九届董事会临时会 议及第九届监事会临时会议，审议通过了《关于公司及子公司使用部分暂时闲置 募集资金进行现金管理的议案》，同意公司及子公司使用不超过7亿元（含本数） 暂时闲置募集资金进行现金管理，投资的产品品种为安全性较高、流动性较好、 风险较低的保本型理财产品。使用期限自公司董事会审议通过之日起12个月内有 效，上述额度在使用期限内可以滚动使用，到期后归还至募集资金专户。 特别风险提示：尽管公司购买的单位大额存单安全性较高、流动性较好、 风险较低，但金融市场受宏观经济的影响较大，公司将根据经济形势以及金融市 场的变化合 ...

Core Points - Nanjing Pharmaceutical Co., Ltd. announced the payment of its third short-term financing bond for 2024, referred to as "24 Nanjing Pharmaceutical SCP003" [1] - The bond has an issuance amount of 500 million yuan, with an interest rate of 1.8% for a term of 269 days [1] - The total amount to be repaid, including principal and interest, is approximately 506.63 million yuan, with the payment date set for September 12, 2025 [1] Summary by Category - **Bond Details** - The bond code is 012483960, and the interest start date is December 17, 2024 [1] - The main underwriter and ongoing management institution is Hangzhou Bank [1] - The registration and custody institution is the National Interbank Funding Center [1]